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108	 patients	 receiving	 a	 trivalent	 seasonal	 influenza	 vaccination	 was	 conducted.	
Influenza‐specific	antibody	titers	(H1N1,	H3N2,	and	influenza	B)	were	measured	to	






etate.	 In	particular	 for	H3N2,	 response	 rates	were	 low	 in	natalizumab‐treated	pa‐




Conclusion:	 Vaccination	 led	 to	 good	 immunogenicity,	 especially	 in	 MS	 patients	
treated	with	interferons	and	glatiramer	acetate.	At	least	for	the	H1N1	strain,	rates	of	
seroprotection	 and	 seroconversion/significant	 titer	 increase	were	 high	 (>70%	 and	
>60%,	respectively)	for	all	therapeutic	subgroups.	Patients	with	a	longer	duration	of	
the	 disease	 are	 exposed	 to	 an	 increased	 risk	 of	 insufficient	 immune	 response	 to	
vaccination.
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risk	 of	 disease	 exacerbation.	 Relapses	 associated	 with	 infections	
more	often	lead	to	a	prolonged	neurological	deficit	or	sustained	de‐
terioration	than	relapses	without	such	an	association.10	MS	patients	




Vaccination	 is	 an	 effective	 tool	 to	 reduce	 infection‐associated	
morbidity	and	mortality.	In	the	past,	its	use	in	MS	was	constrained	
by	 safety	 concerns.14,15	 Retrospective	 and	 prospective	 studies	 so	
far	show	a	complex	situation:	while	yellow	fever	vaccine	may	 lead	
to	 increased	 MS	 activity,	 tetanus	 and	 diphtheria	 vaccination	 do	
not	 generally	 influence	 disease	 manifestation.16‒18	 With	 the	 ex‐
ception	 of	 a	 small	 case	 series,19	 multiple	 studies	 reported	 no	 in‐
creased	relapse	rates	after	vaccination	against	the	 influenza	strain	
A/California/07/2009	 (H1N1),	 which	 has	 been	 circulating	 since	
2009.17,20‒24
Inactivated	influenza	vaccines	are	thus	considered	safe	and	are	











2.1 | Subjects and study procedures
We	 conducted	 a	 prospective,	multicenter,	 non‐randomized	 obser‐
vational	 study.	 The	 participating	 study	 sites	 were	 one	 university	
hospital	 delivering	 outpatient	 care	 and	 27	 specialized	 outpatient	
care	centers	in	Germany.
The	 study	 included	 patients	 with	 MS,	 aged	 18‐70	years,	 who	
were	 treated	 with	 a	 DMT	 for	 at	 least	 6	months	 and	 had	 an	 in‐
dication	 for	 a	 seasonal	 influenza	 vaccination	 according	 to	 the	
German	national	recommendations	by	the	Standing	Committee	on	
























The	 influenza‐specific	 antibody	 titer	 measurements	 were	 carried	
out	 by	 the	 national	 reference	 laboratory	 for	 influenza	 at	 the	 Robert‐





The	 immune	 response	was	 evaluated	 using	 the	 criteria	 of	 the	
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The	activity	of	MS	(relapses	and	progression	of	disability	in	the	
EDSS),	 changes	 of	 DMT,	 new	medical	 conditions,	 and	 changes	 in	
concurrent	medication	were	registered	during	follow‐up	visits	after	
3,	6,	and	12	months.






who	 entered	 the	 study,	 received	 influenza	 vaccination,	 and	 had	
available	antibody	titer	results	at	days	0	and	28.










t‐test,	 Fisher’s	 exact	 test,	 chi‐squared	 test,	McNemar’s	 test,	 and	
Mann‐Whitney	U	test	were	used	when	appropriate.	Nominal	two‐
tailed	 P	 values	 <0.05	 were	 considered	 statistically	 significant.	
Binomial	 logistic	 regression	 was	 performed	 to	 evaluate	 the	 ef‐
fects	of	baseline	variables	on	the	 likelihood	of	 the	outcome.	The	
variables	 entered	 the	 regression	models	 using	 forward	 selection	
(based	on	likelihood	ratio)	statistics.	A	two‐way	ANOVA	was	per‐
formed	for	main	and	interaction	effects	of	DMT	and	relapse	events	












In	 the	year	prior	 to	vaccination,	 the	participants	experienced	0.50	




glatiramer	acetate	 (25.5%),	natalizumab	 (13.7%),	 fingolimod	 (5.9%),	
and	others	(10.8%);	among	these:	glucocorticosteroids	(4.9%),	mitox‐
antrone	(2.0%),	 intravenous	 immunoglobulins	 (2.0%),	teriflunomide	
(1.0%),	and	fumaric	acid	esters	(1.0%).
3.2 | Immunogenicity
Protective	 antibody	 titers	 against	H1N1	prior	 to	 vaccination	were	










3.3 | Seroprotection by therapeutic regimen
Heterogeneous	 seroprotection	 rates	 concerning	 the	 individual	
influenza	 strains	 were	 found	 within	 the	 therapeutic	 subgroups	
(Table	 4).	 While	 there	 were	 no	 significant	 differences	 in	 protec‐
tion	rates	against	H1N1	among	different	DMT,	the	protection	rates	
against	 H3N2	 differed	 significantly	 (chi‐squared	 test,	 P	<	0.001),	




tient	 for	all	 three	 influenza	strains),	 the	seroprotection	rates	dif‐
fered	by	the	DMT	(chi‐squared	test,	P	=	0.002).	In	comparison	to	
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other	 treatments,	 seroprotection	was	highest	 in	 IFN‐treated	pa‐
tients	(Figure	1).
3.4 | Seroprotection by other clinico‐
demographic variables






Considering	all	 strains	 (ie,	 seroprotection	of	an	 individual	pa‐
tient	 against	 all	 three	 influenza	 strains	 in	 combination),	 seropro‐
tection	 after	 vaccination	was	 associated	with	 a	 shorter	 duration	
of	 disease	 (median	 of	 5	years)	 and	 lack	 of	 seroprotection	 was	
associated	with	 a	 longer	 duration	 of	 disease	 (median	 of	 9	years,	
Mann‐Whitney	U	test,	U	=	958.5,	P	=	0.032).	Moreover,	in	men,	se‐
roprotection	against	all	three	strains	was	significantly	less	frequent	
than	 in	women	 (36.0%	 vs	 63.6%,	 Fisher’s	 exact	 test,	P	=	0.020).	
Higher	seroprotection	rates	were	also	seen	 in	patients	who	have	
not	been	treated	with	other	DMT	before	their	current	therapy	ver‐
sus	 those	who	switched	 their	DMT	 in	 the	past	 (72.0%	vs	42.0%,	
chi‐squared	test,	P	=	0.004).
3.5 | Seroconversion or significant titer increase






of	 all	 subjects.	 Statistically	 significant	 differences	 in	 the	duration	
of	 the	 disease	 were	 found	 in	 the	 group	 comparisons:	 adequate	
titer	movements	in	all	three	strains	were	associated	with	a	shorter	
duration	 of	 the	 disease	 (median	 of	 3	years)	 and	 insufficient	 titer	
movements	were	associated	with	a	longer	duration	of	the	disease	
(median	 of	 8	years,	 Mann‐Whitney	 U	 test,	 U	=	721.0,	 P	=	0.018).	
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A	 longer	duration	of	disease	was	a	negative	predictor	 for	se‐
roconversion	 or	 significant	 titer	 increase	 in	 the	 case	 of	 H1N1	
(P	=	0.006,	 OR	=	0.899).	 In	 the	 case	 of	 H3N2,	 the	 model	 indi‐
cated	that	a	previous	DMT	(P	=	0.033,	OR	=	0.352)	and	male	sex	
(P	=	0.012,	OR	=	0.217)	are	negative	predictors	for	seroconversion	
or	 significant	 titer	 increase.	 Regarding	 seroconversion	or	 signifi‐
cant	titer	increase	after	immunization	against	the	B	strain,	the	lo‐
gistic	regression	included	disease	duration	(P	=	0.009,	OR	=	0.892)	
as	 the	 predictive	 variable.	When	 looking	 at	 all	 influenza	 strains,	
again	a	longer	disease	duration	(P	=	0.040,	OR	=	0.910)	was	asso‐
ciated	with	an	insufficient	response	to	the	vaccine.
Thus,	 a	 previous	DMT	 and	 a	 long	 duration	 of	 disease	were	 in	




The	 annual	 relapse	 rate	 in	 the	 year	 before	 vaccination	 was	 0.50	
relapses	per	patient	 (data	for	98/102	patients)	and	 in	the	year	fol‐












Reported	 local	 AE	 were	 mild	 or	 moderate	 pain,	 redness,	 or	





like	 symptoms	 (n	=	3),	 increase	 in	 temperature	 (n	=	2),	 or	 nightly	
sweating	 (n	=	1).	 Six	 patients	 under	 interferon	 treatment	 reported	










Our	 multicenter	 study	 showed	 that	 after	 immunization	 with	 a	
seasonal	 trivalent	 influenza	 vaccine,	 most	 endpoints	 for	 the	 im‐
munogenicity	of	 individual	 influenza	strains	could	be	met	 in	a	het‐
erogeneous	 group	 of	MS	 patients:	 (a)	 for	 each	 strain,	 >70%	 of	 all	
subjects	achieved	an	anti‐HI	titer	≥40,	(b)	for	H1N1	and	H3N2	(but	
not	for	the	B	strain),	>40%	of	all	subjects	achieved	a	seroconversion	
or	significant	 increase	 in	antibody	titers,	and	 (c)	a	mean	geometric	
titer	 increase	 >2.5	 could	 be	 noted	 for	 each	 particular	 strain.	 The	
overall	results	on	immunogenicity	for	the	study	cohort	should,	how‐
ever,	 not	 distract	 from	 those	 subgroups	where	 immunization	 falls	
short	of	a	sufficient	response.
When	 looking	 at	 seroprotection	 in	more	 detail,	 patients	 treated	
with	IFN	reached	seroprotection	rates	of	>80%	for	the	individual	strains	
TA B L E  3  Serum	antibody	titers	and	titer	changes	following	seasonal	influenza	vaccination
A(H1N1)‐California A(H3N2)‐Perth B‐Brisbane All strainsa
Before	vaccination	(baseline)
Seroprotection,	n	(%) 21	(20.6%) 23	(22.5%) 44	(43.1%) 7	(6.8%)
GMT 11 11 22 ‐
After	vaccination	(day	28)
GMT 125 55 63 ‐
GMT	increase 11.2 4.9 2.9 ‐
Seroprotection,	n	(%) 87	(85.3%) 74	(72.5%) 82	(80.4%) 58	(56.9%)
Seroconversion	or	significant	titer	
increase	(all	subjects),	n	(%)
71	(69.6%) 54	(52.9%) 39	(38.2%) 28	(27.5%)
Seroconversion,	n	(%) 47/59	(79.7%) 30/57	(52.6%) 11/17	(64.7%) ‐
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(H1N1	84.4%,	H3N2	91.1%,	B	strain	88.9%).	Protective	antibody	titers	
















In	 patients	 receiving	 natalizumab,	 the	 antibody	 response	 to	
H3N2	was	low	compared	to	H1N1	and	the	B	strain.	It	remains	un‐
clear	 why	 seropositivity	 differs	 to	 that	 extent	 after	 vaccination.	
Previously	 published	 results	 on	 seasonal	 influenza	 vaccination	 in	




demonstrated	 seroprotection	 rates	 against	 H1N1	 comparable	 to	
that	of	healthy	controls	(75.0%	vs	71.2%,	n	=	8).29
Similar	 to	 natalizumab,	 antibody	 response	 to	 H3N2	 in	 fingoli‐
mod‐treated	patients	was	lower	than	to	the	other	antigens,	but	this	







vaccination.32	 In	 contrast,	 H3N2	 seroprotection	 rates	were	 lower	
compared	 to	 our	 study	 in	 case	 of	 IFN‐beta	 (44.0%	 vs	 91.1%)	 and	
glatiramer	 acetate	 (26.1%	 vs	 73.1%)	 therapy.	One	 explanation	 for	
this	difference	might	be	 that	different	H3N2	antigen	 strains	were	
vaccinated	(A/Victoria/361/2011	vs	A/Perth/16/2009).












However,	 these	 factors	 are	not	 independent	 from	each	other	 and	
may	influence	therapeutic	decisions.	Moreover,	immunosenescence	





and	 EDSS)	 was	 not	 increased	 during	 one	 year	 after	 vaccination.	
Vaccination	was	 well	 tolerated	 overall.	 The	 rate	 of	 local	 and	 sys‐
temic	AE	was	 low	compared	 to	 influenza	vaccine	approval	 studies	
(17.6%	of	MS	subjects	affected	by	AE	vs	64.0%	of	healthy	non‐el‐
derly	adults).39	However,	 the	 lower	 rates	of	AE	may	be	due	 to	 re‐
porting	 differences.	 This	 study	 relied	 on	 self‐reporting	 of	 events	






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































significant	 difference	 for	 baseline	 variables.	 The	 female:male	 sex	
ratio	of	3:1	is	similar	to	the	higher	share	of	women	affected	by	mul‐










subjects	were	 small,	both	 in	 this	 study	and	a	previous	evaluation.32 
One	 must	 bear	 in	 mind	 that	 the	 detected	 antibody	 response	 only	
serves	as	a	surrogate	marker	for	protection	against	influenza	infection.












immune	 response	 to	 vaccination.	 Otherwise,	 seasonal	 influenza	
immunization	in	MS	is	safe	and	well	tolerated.	Seasonal	influenza	
vaccination	thus	should	be	attempted	to	achieve	the	best	possible	
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